Abstract
AbstractThe neutralization of tumor necrosis factor alpha (TNFα) with biopharmaceuticals is a successful therapy for inflammatory diseases. Currently, one of the main TNFα‐antagonists is Etanercept, a dimeric TNF‐R2 ectodomain. Considering that TNFα and its receptors are homotrimers, we proposed that a trimeric TNF‐R2 ectodomain could be an innovative TNFα‐antagonist. Here, the 3cTNFR2 protein was designed by the fusion of the TNF‐R2 ectodomain with the collagen XV trimerization domain. 3cTNFR2 was produced in HEK293 cells and purified by immobilized metal affinity chromatography. Monomers, dimers, and trimers of 3cTNFR2 were detected. The interaction 3cTNFR2‐TNFα was assessed. By microscale thermophoresis, the KD value for the interaction was 4.17 ± 0.88 nM, and complexes with different molecular weights were detected by size exclusion chromatography‐high performance liquid chromatography. Moreover, 3cTNFR2 neutralized the TNFα‐induced cytotoxicity totally in vitro. Although more studies are required to evaluate the anti‐inflammatory effect, the results suggest that 3cTNFR2 could be a TNFα‐antagonist agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
